|
|
| | clitocine Basic information |
| Product Name: | clitocine | | Synonyms: | clitocine;b-D-RibofuranosylaMine, N-(6-aMino-5-nitro-4-pyriMidinyl)-;β-D-Ribofuranosylamine, N-(6-amino-5-nitro-4-
pyrimidinyl)-;N-(6-Amino-5-nitro-4-pyrimidinyl)-beta-D-ribofuranosylamine;N-(6-Amino-5-nitro-4-pyrimidinyl)-β-D-ribofuranosylamine;N-?(6-?amino-?5-?nitro-?4-?pyrimidinyl)?-β-?D-?Ribofuranosylamine | | CAS: | 105798-74-1 | | MF: | C9H13N5O6 | | MW: | 287.231 | | EINECS: | | | Product Categories: | | | Mol File: | 105798-74-1.mol |  |
| | clitocine Chemical Properties |
| | clitocine Usage And Synthesis |
| Definition | ChEBI: Clitocine is a N-glycosyl compound. | | Biological Activity | Clitocine, an adenosine nucleoside analog derived from mushrooms, is a potent readthrough. As an inhibitor of nonsense mutations, it can induce the production of p53 protein in cells carrying p53 nonsense mutant alleles. It induces apoptosis in multidrug-resistant tumor cells by targeting Mcl-1. Has anticancer activity. | | in vitro | Clitocine incorporation into mRNA is required for premature stop codon readthrough activity, and the presence of clitocine at the third position of a premature stop codon is sufficient to promote robust readthrough.
Clitocine (0-0.8 μM ; 24 hours) enhances TRAIL-lethality in in LS411N and SW620 cells. It (0.2μM; 36 hours) significantly potentiates TRAIL-mediated apoptosis. div> | | in vivo | Citocine (0.3-3 mg/kg; sc; five times per week)-induced p53 inhibits CAOV-33 p53-UAA136 tumor growth in a xenograft model. < td class="col1 fwb"> Animal Model: | nu/nu mice (CAOV-3p53-UAA136 xenograft tumors) | | Dosage: | 0.3, 3 mg/kg (or 20 mg/kg once per week) | | Administration: | Sc; five times per week | | Result: | CAOV-33 p53-UAA136 tumor growth was inhibited. | |
| | clitocine Preparation Products And Raw materials |
|